

**2**

# **Topics in Medicinal Chemistry**

**Editorial Board:**

**P. R. Bernstein · A. Buschauer · J. A. Lowe · H. U. Stilz**

# Alzheimer's Disease

Volume Editors: Lit-Fui Lau · Michael A. Brodney

With contributions by

S. Berg · R. V. Bhat · M. A. Brodney · J. Burrows · A. I. Bush  
G. Grossberg · L.-F. Lau · J. Lindquist · Q. Jiang · J. Kao · G. Landreth  
S. Mandrekar · H. D. Soares · D. L. Sparks · A. R. White

Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the new topic-related series should cover all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics.

In references *Topics in Medicinal Chemistry* is abbreviated *Top Med Chem* and is cited as a journal.

Springer WWW home page: [springer.com](http://springer.com)  
Visit the TIMC content at [springerlink.com](http://springerlink.com)

Library of Congress Control Number: 2007935106

ISSN 1862-2461

ISBN 978-3-540-74228-9 Springer Berlin Heidelberg New York

DOI 10.1007/978-3-540-74229-6

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable for prosecution under the German Copyright Law.

**Springer is a part of Springer Science+Business Media**

[springer.com](http://springer.com)

© Springer-Verlag Berlin Heidelberg 2008

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Cover design: WMXDesign GmbH, Heidelberg

Typesetting and Production: LE-TeX Jelonek, Schmidt & Vöckler GbR, Leipzig

Printed on acid-free paper 02/3180 YL – 5 4 3 2 1 0

---

## Volume Editors

Dr. Lit-Fui Lau

CNS Discovery  
Pfizer Global Research & Development  
Groton, CT 06340  
USA  
lit-fui.lau@pfizer.com

Dr. Michael A. Brodney

CNS Discovery  
Pfizer Global Research & Development  
Groton, CT 06340  
USA  
michael.a.brodney@pfizer.com

## Editorial Board

Dr. Peter R. Bernstein

AstraZeneca Pharmaceuticals  
1800 Concord Pike  
Fairfax Research Center B313  
PO Box 15437  
Wilmington, DE 19850-5437  
USA

Prof. Dr. Armin Buschauer

Inst. f. Pharmazie  
Universität Regensburg  
Universitätsstr. 31  
93053 Regensburg

Prof. John A. Lowe

Pfizer Inc.  
MS 8220-4118  
Eastern Point Road  
Groton, CT 06340  
USA

Dr. Hans Ulrich Stilz

Aventis Pharma Deutschland GmbH  
Geb. G 838  
65926 Frankfurt a.M.

---

## **Topics in Medicinal Chemistry Also Available Electronically**

For all customers who have a standing order to Topics in Medicinal Chemistry, we offer the electronic version via SpringerLink free of charge. Please contact your librarian who can receive a password or free access to the full articles by registering at:

[springerlink.com](http://springerlink.com)

If you do not have a subscription, you can still view the tables of contents of the volumes and the abstract of each article by going to the SpringerLink Homepage, clicking on “Browse by Online Libraries”, then “Chemical Sciences”, and finally choose Topics in Medicinal Chemistry.

You will find information about the

- Editorial Board
- Aims and Scope
- Instructions for Authors
- Sample Contribution

at [springer.com](http://springer.com) using the search function.

---

## Preface to the Series

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug discovery is uniquely beneficial to the field of medicinal chemistry.

The series *Topics in Medicinal Chemistry* is designed to help both novice and experienced medicinal chemists share insights from the drug discovery process. For the novice, the introductory chapter to each volume provides background and valuable perspective on a field of medicinal chemistry not available elsewhere. Succeeding chapters then provide examples of successful drug discovery efforts that describe the most up-to-date work from this field.

The editors have chosen topics from both important therapeutic areas and from work that advances the discipline of medicinal chemistry. For example, cancer, metabolic syndrome and Alzheimer's disease are fields in which academia and industry are heavily invested to discover new drugs because of their considerable unmet medical need. The editors have therefore prioritized covering new developments in medicinal chemistry in these fields. In addition, important advances in the discipline, such as fragment-based drug design and other aspects of new lead-seeking approaches, are also planned for early volumes in this series. Each volume thus offers a unique opportunity to capture the most up-to-date perspective in an area of medicinal chemistry.

Dr. Peter R. Bernstein  
Prof. Dr. Armin Buschauer  
Dr. John Lowe  
Dr. Hans Ulrich Stilz

---

## Preface to Volume 2

It was one hundred and one years ago that Alois Alzheimer presented at a scientific meeting a case of progressive dementia in a 51-year-old patient Auguste D. Postmortem analysis revealed two pathologies, namely, senile plaques and neurofibrillary tangles. These findings were published the following year in 1907. In 1910 Emil Kraepelin, Alzheimer's mentor, named this disease after its discoverer. The two initial pathological findings remain the postmortem diagnostic features of Alzheimer's disease (AD) today. At the time, however, Kraepelin made the distinction between AD and senile dementia (> 65 years old) despite their similarities in pathologies and clinical symptoms [1, 2]. In 1976 Robert Katzman argued in an editorial in the April issue of *Archives of Neurology* that this distinction be removed. AD has thus morphed from a rare orphan disease to one with a much bigger socioeconomic threat. This nosological shift has brought AD into the lime light and exponentially—and thankfully—hastened the pace of research. Enormous strides have been made in understanding the root causes and risk factors of the disease. Analogous to the discovery of new cancer treatments over the past 20 years (see Volume 1), advances in understanding the underlying molecular biology are providing novel drug targets for future research. These efforts have resulted in greater than 500 ongoing clinical trials focused on novel mechanisms and intervention points in the disease. These trials will hopefully lead to the first approval of a disease-modifying agent for AD and pave the way for an arsenal of new medications.

October, 2007, Groton  
Connecticut, USA

Lit-Fui Lau and Michael A. Brodney

1. Ballenger JF (2006) *J Alzheimers Dis* 9:5
2. Lage JM (2006) *J Alzheimers Dis* 9:15

---

# Contents

<b>Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview</b>	
L.-F. Lau · M. A. Brodney . . . . .	1
<b>Cholinesterase Inhibitors</b>	
J. Kao · G. Grossberg . . . . .	25
<b>Beyond Cholesterol: Statin Benefits in Alzheimer's Disease</b>	
H. D. Soares · D. L. Sparks . . . . .	53
<b>PPAR<math>\gamma</math> Agonists for the Treatment of Alzheimer's Disease</b>	
Q. Jiang · S. Mandrekar · G. Landreth . . . . .	81
<b>Metal Complexing Agents for the Treatment of Alzheimer's Disease</b>	
A. R. White · A. I. Bush . . . . .	107
<b>GSK-3 Inhibitors for the Treatment of Alzheimer's Disease</b>	
R. V. Bhat · S. Berg · J. Burrows · J. Lindquist . . . . .	137
<b>Author Index Volumes 1–2 . . . . .</b>	<b>175</b>
<b>Subject Index . . . . .</b>	<b>177</b>